Mekonos is a Silicon Valley Venture-backed technology company — creating a proprietary cell-engineering platform based on scalable silicon technology for our partners engaged in drug discovery and development.
Location: United States, California, San Francisco
Employees: 11-50
Total raised: $29.6M
Founded date: 2017
Investors 9
Funding Rounds 2
| Date | Series | Amount | Investors |
| 10.11.2021 | Series A | $25M | - |
| 04.12.2020 | - | $4.6M | - |
Mentions in press and media 9
| Date | Title | Description |
| 10.11.2021 | Mekonos closes an oversubscribed, Novartis-backed $25M Series A to Expand Their Cell Engineering Platform | Mekonos continues to build critical infrastructure which can unlock personalized medicine at scale and enable cell engineering across life science verticals. Using its proprietary “system-on-a-chip” platform, Mekonos uses arrays of hundreds... |
| 10.11.2021 | Mekonos Raises $25M in Series A Funding | Mekonos, a San Francisco CA-based biotech company transforming synthetic biology and personalized medicine, raised $25M in Series A funding. The round was led by Reimagined Ventures, Fiscus Ventures, and PEAK6 Strategic Capital, Section 32,... |
| 09.11.2021 | Biotech Startup Mekonos raises oversubscribed $25 million round to overcome pharma industry's cell & gene therapy delivery hurdles | SAN FRANCISCO, Nov. 9, 2021 /PRNewswire/ -- Mekonos, a biotech company building the future of cell therapies on a chip, has raised $25M in an oversubscribed Series A round co-led by Reimagined Ventures, Fiscus Ventures, and PEAK6 Strategic ... |
| 09.11.2021 | Mekonos, Inc. announced that it has received $25 million in funding from a group of investors | On November 9, 2021, Mekonos, Inc. closed the transaction. The company has raised $25,000,000 in the transaction co-led by new investors Reimagined Ventures, LLC, Fiscus Ventures, and PEAK6 Investments LLC. The transaction included particip... |
| 09.11.2021 | TDK Ventures backs MEMS-based genome editing tools company, Mekonos | SAN JOSE, Calif. , Nov. 9, 2021 /PRNewswire/ -- TDK Corporation (TSE: 6762) announced today that subsidiary TDK Ventures, Inc., has invested in biotech tools company Mekonos to accelerate the development and deployment of Mekonos' integrate... |
| 09.11.2021 | Mekonos Raises $25M Series A Round | SAN FRANCISCO, CA, Mekonos, a biotech company building the future of cell therapies on a chip, has raised $25 million in an oversubscribed Series A round. >> Click here for more funding data on Mekonos >> To export Mekonos f... |
| 09.11.2021 | Mekonos closes Novartis-backed $25M series A for cell engineering platform | Many of the rarest and hardest-to-treat diseases are caused by a single defect in a specific gene, making them difficult to target with traditional pharmaceutical or surgical methods. Instead, cell and gene therapies have emerged as more ef... |
| 04.12.2020 | Mekonos Raises $4.6M in Funding | Mekonos, a San Francisco, CA-based biotech company launching a system-on-a-chip (SoC) for targeted ex vivo gene engineering, completed a $4.6m financing round. The round was led by Novartis AG with participation from institutional VCs inclu... |
| 26.11.2020 | Mekonos raises $4.6M for its gene engineering platform | Mekonos, a biotech company launching the first-of-its kind system-on-a-chip (SoC) for targeted ex vivo gene engineering, today announced it has completed a $4.6 million financing round. Mekonos will use the new capital to accelerate the SoC... |